[May 07, 2014] |
|
Research and Markets: Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/shrt7g/endometrial)
has announced the addition of the "Endometrial
Cancer - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Endometrial Cancer, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Endometrial Cancer and special features on late-stage and discontinued
projects.
The report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from proprietary databases,
Company/University websites, SEC (News - Alert) filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources.
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
Companies Involved:
-
AEterna Zentaris Inc.
-
Acceleron Pharma, Inc.
-
ArQule, Inc.
-
Ariad Pharmaceuticals, Inc.
-
Arno Therapeutics, Inc.
-
Boehringer Ingelheim GmbH
-
Bristol-Myers Squibb Company
-
Critical Outcome Technologies Inc.
-
Eisai Co., Ltd.
-
Esperance Pharmaceuticals, Inc.
-
Exelixis, Inc.
-
Galena Biopharma, Inc.
-
GlaxoSmithKline plc
-
Igenica, Inc.
-
ImmunoGen, Inc.
-
Ipsen S.A.
-
Merck & Co., Inc.
-
Novartis AG
-
OncoHoldings, Inc.
-
Oryzon Genomics S.A.
-
Pfizer Inc.
-
Pharmsynthez
-
Scancell Holdings Plc
-
Taiho Pharmaceutical Co., Ltd.
Drug Profiles:
-
zoptarelin doxorubicin
-
ixabepilone
-
lenvatinib
-
MK-2206
-
PF-05212384
-
ridaforolimus
-
dalantercept
-
cabozantinib (s)-malate
-
nintedanib
-
EP-100
-
dovitinib lactate
-
buparlisib hydrochloride
-
Virexxa
-
GALE-301
-
GSK-2636771
-
GSK-2141795
-
GSK-2256098
-
GSK-2141795 + trametinib
-
IMGN-853
-
ARQ-092
-
onapristone ER
-
COTI-2
-
EP-200
-
ONCO-101
-
TAS-2985
-
SERD 2
-
(ponatinib + ridaforolimus)
-
Virexxa
-
Monoclonal Antibody For Endometrial Cancer
-
Small Molecules for Oncology and Infectious Disease
For more information visit http://www.researchandmarkets.com/research/shrt7g/endometria
[ Back To TMCnet.com's Homepage ]
|